Fintel reports that on October 27, 2025, Canaccord Genuity maintained coverage of Exagen (NasdaqGM:XGN) with a Buy recommendation.
Analyst Price Forecast Suggests 0.10% Downside
As of September 30, 2025, the average one-year price target for Exagen is $11.95/share. The forecasts range from a low of $10.10 to a high of $15.75. The average price target represents a decrease of 0.10% from its latest reported closing price of $11.96 / share.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Exagen is 79MM, an increase of 33.80%. The projected annual non-GAAP EPS is -2.28.
What is the Fund Sentiment?
There are 85 funds or institutions reporting positions in Exagen. This is an increase of 24 owner(s) or 39.34% in the last quarter. Average portfolio weight of all funds dedicated to XGN is 0.13%, an increase of 93.47%. Total shares owned by institutions increased in the last three months by 53.38% to 9,729K shares. 
The put/call ratio of XGN is 0.13, indicating a bullish outlook.
What are Other Shareholders Doing?
Rtw Investments holds 1,697K shares representing 7.71% ownership of the company. In its prior filing, the firm reported owning 1,512K shares , representing an increase of 10.90%. The firm increased its portfolio allocation in XGN by 103.21% over the last quarter.
Toronto Dominion Bank holds 851K shares representing 3.87% ownership of the company. In its prior filing, the firm reported owning 891K shares , representing a decrease of 4.71%. The firm decreased its portfolio allocation in XGN by 37.36% over the last quarter.
Balyasny Asset Management holds 719K shares representing 3.27% ownership of the company.
Silvercrest Asset Management Group holds 532K shares representing 2.42% ownership of the company. No change in the last quarter.
Driehaus Capital Management holds 481K shares representing 2.19% ownership of the company. In its prior filing, the firm reported owning 419K shares , representing an increase of 12.98%. The firm increased its portfolio allocation in XGN by 85.45% over the last quarter.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
